Natural bioactive compounds: a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment?

Abstract

Bladder cancer (BC) is the tenth most common cancer, and its incidence is steadily rising worldwide, with the highest rates in developed countries. Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the standard therapy for patients with muscle-invasive bladder cancer. However, less than 50% of patients initially respond to this treatment and nearly all of them eventually develop resistance, which is an important barrier to long-term survival. Therefore, there is an urgent need to understand the mechanisms of cisplatin resistance in BC and develop ways to counteract them. Several preclinical studies have demonstrated that naturally derived bioactive compounds, such as phytochemicals and flavonoids, can enhance the antitumor activity of cisplatin, with minimal side effects, by targeting different pathways involved in cisplatin sensitivity and resistance. However, their poor bioavailability has been one of the main problems for their successful introduction into clinical practice. At present, however, many new formulations with greatly increased bioavailability are under study in several clinical trials with encouraging results.

Keywords

Bladder cancer / muscle-invasive bladder cancer / cisplatin / chemoresistance / natural products / curcumin / bioavailability

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[2] Siegel RL,Jemal A.Cancer statistics, 2019.CA Cancer J Clin2018;69:7-34

[3] Knowles MA.Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Nat Rev Cancer2015;15:25-41

[4] Grossman HB,Tangen CM.Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.N Engl J Med2003;349:859-66

[5] Pardo JC,Plaja A.Moving towards personalized medicine in muscle-invasive bladder cancer: where are we now and where are we going?.Int J Mol Sci2020;21:6271 PMCID:PMC7503307

[6] Leow JJ,Rajagopal PS.Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.Eur Urol2014;66:42-54

[7] Cognetti F,Felici A.Study Group(†)Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.Ann Oncol2012;23:695-700

[8] Stadler WM,Groshen S.Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.J Clin Oncol2011;29:3443-9 PMCID:PMC3164246

[9] Bellmunt J,Mead GM.Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987.J Clin Oncol2012;30:1107-13 PMCID:PMC3341152

[10] Balar AV,Rosenberg JE.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet2017;389:67-76 PMCID:PMC5568632

[11] Bellmunt J,Vaughn DJ.KEYNOTE-045 InvestigatorsPembrolizumab as second-line therapy for advanced urothelial carcinoma.N Engl J Med2017;376:1015-26 PMCID:PMC5635424

[12] Kalbasi A.Tumour-intrinsic resistance to immune checkpoint blockade.Nat Rev Immunol2020;20:25-39 PMCID:PMC8499690

[13] Kaur J,Geynisman DM,Ghatalia P.Role of immunotherapy in localized muscle invasive urothelial cancer.Ther Adv Med Oncol2021;13:17588359211045858 PMCID:PMC8461126

[14] Rajendran G,Woolbrigh BL.Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer.Cancer Drug Resist2021;4:69-84

[15] Amable L.Cisplatin resistance and opportunities for precision medicine.Pharmacol Res2016;106:27-36

[16] Sun CY,Zheng GJ.Phytochemicals: current strategy to sensitize cancer cells to cisplatin.Biomed Pharmacother2019;110:518-27

[17] de Porras V, Layos L, Martínez-Balibrea E. Curcumin: a therapeutic strategy for colorectal cancer?.Semin Cancer Biol2021;73:321-30

[18] Font A,Valderrama BP.Epithelial-to-mesenchymal transition mediates resistance to maintenance therapy with vinflunine in advanced urothelial cell carcinoma.Cancers (Basel)2021;13:6235 PMCID:PMC8699401

[19] Ruiz de Porras V,Martínez-Cardús A.Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway.Sci Rep2016;6:24675 PMCID:PMC4835769

[20] Giordano A.Curcumin and cancer.Nutrients2019;11:2376 PMCID:PMC6835707

[21] Park BH,Jeon HG.Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2.Oncotarget2016;7:63870-86 PMCID:PMC5325410

[22] Kao CC,Yang MH.Demethoxycurcumin induces apoptosis in HER2 overexpressing bladder cancer cells through degradation of HER2 and inhibiting the PI3K/Akt pathway.Environ Toxicol2021;36:2186-95

[23] Abadi AJ,Mahabady MK.Curcumin and its derivatives in cancer therapy: potentiating antitumor activity of cisplatin and reducing side effects.Phytother Res2022;36:189-213

[24] Hussain Y,Khan H,Aschner M.Curcumin-cisplatin chemotherapy: a novel strategy in promoting chemotherapy efficacy and reducing side effects.Phytother Res2021;35:6514-29

[25] Prasad S,Aggarwal BB.Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice.Cancer Res Treat2014;46:2-18 PMCID:PMC3918523

[26] Cas M, Ghidoni R. Dietary curcumin: correlation between bioavailability and health potential.Nutrients2019;11:2147 PMCID:PMC6770259

[27] Sohn SI,Balasubramaniam B.Biomedical applications and bioavailability of curcumin-an updated overview.Pharmaceutics2021;13:2102 PMCID:PMC8703330

[28] Stohs SJ,Ray SD,Bucci LR.Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review.Molecules2020;25:1397 PMCID:PMC7144558